RxDoctor Payments Data

Eamon Dutta, MD

Psychiatry · Atlanta, GANPI 1396822979

Payments from drug & device makers

$15,333in general payments, 2019–2025

Across 802 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • plus $6K from 25 others

What the payments were for

  • Food & beverage$15,286100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,333 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$61,646
Medicare patients
84
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine37$355,125
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl49$8,522
Sertraline Hcl50$1,887
Duloxetine Hcl61$1,779
Desvenlafaxine Succinate ErDesvenlafaxine Succinate31$1,725
Doxepin Hcl41$1,630
Buspirone Hcl134$1,500
Clozapine26$1,353
Mirtazapine110$1,223
Aripiprazole13$1,126
Olanzapine24$1,079
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine37$986
Methylphenidate Er (La)Methylphenidate Hcl11$950
Escitalopram Oxalate73$881
Bupropion XlBupropion Hcl25$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$957$355,12537 claims
Almatica Pharma LLCSertraline Hcl$25$1,88750 claims
Lilly USA, LLCOlanzapine$20$1,07924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →